Daratumumab for the Treatment of Patients With AL Amyloidosis | stella

Learn Data For Researchers Find trials matched to me

Learn Data For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Daratumumab for the Treatment of Patients With AL Amyloidosis | stella

Back to AL Amyloidosis trials

Completed

Plain-English translation of NCT02841033 on ClinicalTrials.gov ↗ · Source last updated May 2021 · How we translate trials

Read our Amyloidosis research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(1 site)

United States

Boston Medical Center, Boston, Massachusetts

Results

Read the full plain-English summary of this trial →

Key details

Phase

Safety & dosing / Early efficacy

Sponsor

Boston Medical Center

Collaborators

Janssen Pharmaceuticals

Enrollment target

~22 participants

Started

March 2017

Primary completion

May 2020

View full record on ClinicalTrials.gov

Age range

18 Years and older

Last updated on clinicaltrials.gov in May 2021.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.